NEW YORK, Oct 1- U.S. stocks dropped more than 1 percent on Wednesday as the first diagnosis of Ebola in a patient in the United States spooked investors, economic data pointed to uneven growth, and the Russell 2000 index entered correction territory.» Read More
The American Society of Clinical Oncology annual meeting, which starts today in Chicago, couldn't get any bigger for ImClone Systems and its Erbitux partners Bristol-Myers Squibb and the German Merck (no relation to the U.S.-based Merck).
First, in the front section, Pfizer is launching a new offensive (or maybe it's defensive?) campaign on the embattled anti-smoking drug Chantix. In a full-page message signed by the company's Chief Medical Officer, Pfizer says, among other things that it's "committed to patient safety (and) furthering our knowledge of Chantix."
With the ASCO conference beginning Friday new cancer drugs are likely to grab headlines. How should you trade ahead of biotech’s biggest weekend?
D-mab is a twice-a-year shot and Fosamax is a once-a-week pill. Doctors say compliance--patients taking their meds--is a challenge with the most common osteoporosis drugs in part because you have to take them with a tall glass of water and then stay upright for at least half an hour.
A bout of risk aversion dented European stocks on Tuesday as jitters grew over potential credit-related problems at banks and inflation, while typically defensive stocks such as pharmaceuticals and food rallied.
I'm thinkin' those two drug giants are champin' at the bit for the docs to get McCain off generic Zocor and onto Lipitor or Crestor. On recent conference calls, some PFE officials have said they think a lot of patients who've had a similar experience to McCain's will eventually come back around to Lipitor.
My recent post on the new Evista commercial from Eli Lilly elicited a few opinions including one from a woman who says she participated in a focus group for the spot. Laura Bliss says her comments at the time were that the "togas...made the women look like they were already sick....
It just keeps getting worse. Pfizer, which is staring down the loss of a $13 billion-a-year drug (Lipitor) in the 2010-11 timeframe, needs the rest of its product portfolio and its drug development pipeline to be firing on all cylinders.
Which stocks will be the winners and losers under an Obama administration? And how about McCain?
So, Carl Icahn is grabbing headlines this week over his new battle with Yahoo and how Boone Pickens is backing him up now, too. But Icahn has his finger in a lot of pies. He's still in a proxy fight with Biogen Idec where he's trying to get his people on the Board at the upcoming shareholder meeting on June 19th.
Sanofi-Aventis' experimental drug aflibercept failed to meet its goal in a mid-stage ovarian cancer study but the French drug maker said on Wednesday it had shown some promising signs of effectiveness.
If sales of Amgen's anemia drugs hadn't fallen so much last year, the American biotechnology industry probably would have turned its first profit in history. That's one of the main conclusions of Ernst & Young's comprehensive annual report on the sector that came out today.
A study claims "the time has come" for researchers to study ED drugs as preventive medicine for the heart.
Up until last month, AMGN had been atop the list of pharmaceutical manufacturer donors and PFE was in a close second. But the CRP says they flip-flopped in the most recent month that figures are available. So far, in the 2008 election cycle, Pfizer's given $862,000 to candidates and Amgen has forked over $852,000.
There's way too much stuff out of ASCO to do a comprehensive blog entry that would satisfy readers--especially small-cap biotechies. I mean, there are literally thousands of pages of research being published today by analysts on the new data.
Genentech said on Thursday a trial of Avastin in colon cancer patients who have undergone surgery will be completed earlier than expected due to faster collection of data and a higher-than-planned number of patients with stage III cancer.
Traders will be glued to the web Thursday night as thousands of cancer studies go online. What’s the trade as these studies potentially send shock waves through biotech stocks on Friday morning?
This is gonna be a crazy couple of days. At 9 pm ET tonight the American Society of Clinical Oncology is putting nearly 5,000 studies on its website all at once. Although ASCO says it's all about the science and protecting the "scientific integrity" of its upcoming conference, this is, frankly, an attempt to level the playing field for Wall Street.
I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.
I realize it's become a bit of a tired tagline, but through the magic of live webcasts what happens in Vegas doesn't stay in Vegas. This morning Dendreon was first at bat at the Bank of America Healthcare Conference in Sin City.